NO331990B1 - Suspensjon som omfatter oxcarbazepin - Google Patents

Suspensjon som omfatter oxcarbazepin Download PDF

Info

Publication number
NO331990B1
NO331990B1 NO20022849A NO20022849A NO331990B1 NO 331990 B1 NO331990 B1 NO 331990B1 NO 20022849 A NO20022849 A NO 20022849A NO 20022849 A NO20022849 A NO 20022849A NO 331990 B1 NO331990 B1 NO 331990B1
Authority
NO
Norway
Prior art keywords
suspension
oxcarbazepine
composition according
antioxidant
container
Prior art date
Application number
NO20022849A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022849L (no
NO20022849D0 (no
Inventor
Juergen Sigg
Michael Billington
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10866648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO331990(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20022849L publication Critical patent/NO20022849L/no
Publication of NO20022849D0 publication Critical patent/NO20022849D0/no
Publication of NO331990B1 publication Critical patent/NO331990B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
NO20022849A 1999-12-20 2002-06-14 Suspensjon som omfatter oxcarbazepin NO331990B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9930058.4A GB9930058D0 (en) 1999-12-20 1999-12-20 Organic compounds
PCT/EP2000/012968 WO2001045671A2 (en) 1999-12-20 2000-12-19 Suspension comprising oxcarbazepine

Publications (3)

Publication Number Publication Date
NO20022849L NO20022849L (no) 2002-06-14
NO20022849D0 NO20022849D0 (no) 2002-06-14
NO331990B1 true NO331990B1 (no) 2012-05-21

Family

ID=10866648

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022849A NO331990B1 (no) 1999-12-20 2002-06-14 Suspensjon som omfatter oxcarbazepin

Country Status (33)

Country Link
US (1) US8119148B2 (de)
EP (2) EP1239832B1 (de)
JP (2) JP4588281B2 (de)
KR (2) KR20040098034A (de)
CN (1) CN1216594C (de)
AR (1) AR030175A1 (de)
AT (1) ATE269694T1 (de)
AU (1) AU777619B2 (de)
BE (2) BE1013706A5 (de)
BR (1) BR0016524A (de)
CA (1) CA2390029C (de)
CO (1) CO5261608A1 (de)
CZ (1) CZ302737B6 (de)
DE (1) DE60011809T2 (de)
DK (1) DK1239832T3 (de)
ES (1) ES2223641T3 (de)
FR (1) FR2802423B1 (de)
GB (1) GB9930058D0 (de)
HU (1) HU226486B1 (de)
IL (2) IL149498A0 (de)
IT (1) ITMI20002717A1 (de)
MX (1) MXPA02006142A (de)
MY (1) MY126868A (de)
NO (1) NO331990B1 (de)
NZ (1) NZ518755A (de)
PE (1) PE20010933A1 (de)
PL (1) PL201331B1 (de)
PT (1) PT1239832E (de)
RU (1) RU2277912C2 (de)
SK (1) SK287553B6 (de)
TR (2) TR200402419T4 (de)
WO (1) WO2001045671A2 (de)
ZA (1) ZA200204863B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
WO2004026263A2 (en) 2002-09-20 2004-04-01 Fmc Corporation Cosmetic composition containing microcrystalline cellulose
DE602004023861D1 (de) 2003-09-03 2009-12-10 Novartis Ag Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007007182A2 (en) * 2005-07-08 2007-01-18 Aurobindo Pharma Limited Solid and liquid dosage forms of an antiepileptic agent
WO2007052289A2 (en) 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
EP2359830B1 (de) * 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Oxcarbazepinpräparate für kontrollierte Freisetzung mit sigmoidalem Freisetzungsprofil
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
CA2773249A1 (en) * 2009-09-10 2011-03-17 Bial-Portela & C.A., S.A. Oral suspension formulations of esclicarbazepine acetate
CN104288104A (zh) * 2014-09-24 2015-01-21 万特制药(海南)有限公司 奥卡西平干混悬剂及其制备方法
EP3397253A1 (de) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit krämpfen
CN109010322A (zh) * 2018-07-13 2018-12-18 山东达因海洋生物制药股份有限公司 一种包含奥卡西平的口腔分散膜剂及其制备方法
CN115487145B (zh) * 2022-10-10 2023-09-01 上海奥科达医药科技股份有限公司 一种奥卡西平口服混悬液及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4004029A (en) * 1974-05-13 1977-01-18 The Upjohn Company Compositions and method for treating epilepsy and convulsions
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
RO81639A2 (ro) * 1981-02-27 1983-06-01 Intreprinderea De Medicamente "Biofarm",Ro Procedeu de obtinere a unei pulberi suspendabile oxrale de ampicilina
CH649080A5 (de) 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4427681A (en) 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
JPS60204713A (ja) 1984-03-30 1985-10-16 Zenyaku Kogyo Kk 水性懸濁組成物
US4693901A (en) 1985-12-10 1987-09-15 Cardinal Biological, Ltd. Shelf stable dairylike products
GB8618847D0 (en) 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
IL90245A (en) 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
ES2054089T3 (es) 1988-11-10 1994-08-01 Ciba Geigy Ag Formulaciones orales liquidas.
GB9102579D0 (en) 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
US5272137A (en) 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9219524D0 (en) * 1992-09-15 1992-10-28 Smithkline Beecham Plc Novel composition
FR2699077B1 (fr) 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
FR2702148B1 (fr) 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2702151B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2702149B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
DE4423078B4 (de) * 1994-07-01 2005-01-13 Awd.Pharma Gmbh & Co. Kg Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
JPH10511640A (ja) 1994-10-14 1998-11-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ サベルゾール経口懸濁剤
DE4443966A1 (de) * 1994-12-09 1996-06-13 Basf Ag Thermoplastische Formmassen
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IT1277663B1 (it) 1995-09-28 1997-11-11 Crinos Industria Farmaco Sospensioni acquose stabili di mesalazina per uso topico
PT101876B (pt) * 1996-05-27 1999-09-30 Portela & Ca Sa Novos derivados de 10,11-di-hidro-10-oxo-5h-dibenzo(b,f)azepina-5-carboxamida
IT1286496B1 (it) 1996-11-20 1998-07-15 Leetrim Ltd Dublin Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
US6037380A (en) * 1997-04-11 2000-03-14 Fmc Corporation Ultra-fine microcrystalline cellulose compositions and process
US6146876A (en) * 1999-06-11 2000-11-14 Millennium Pharmaceuticals, Inc. 22025, a novel human cyclic nucleotide phosphodiesterase
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20030004155A1 (en) 2003-01-02
IL149498A0 (en) 2002-11-10
PL355535A1 (en) 2004-05-04
MXPA02006142A (es) 2002-12-05
TR200201459T2 (tr) 2002-09-23
GB9930058D0 (en) 2000-02-09
ATE269694T1 (de) 2004-07-15
NO20022849L (no) 2002-06-14
PE20010933A1 (es) 2001-09-17
MY126868A (en) 2006-10-31
WO2001045671A2 (en) 2001-06-28
IL149498A (en) 2011-05-31
BE1013706A5 (fr) 2002-06-04
KR100496368B1 (ko) 2005-06-21
AU2511801A (en) 2001-07-03
NO20022849D0 (no) 2002-06-14
PL201331B1 (pl) 2009-03-31
CZ302737B6 (cs) 2011-10-12
DK1239832T3 (da) 2004-08-09
WO2001045671A3 (en) 2002-02-21
HUP0203782A2 (hu) 2003-03-28
HU226486B1 (en) 2009-03-02
FR2802423A1 (fr) 2001-06-22
ES2223641T3 (es) 2005-03-01
EP1239832A2 (de) 2002-09-18
ITMI20002717A1 (it) 2002-06-15
DE60011809D1 (en) 2004-07-29
TR200402419T4 (tr) 2004-12-21
KR20020062658A (ko) 2002-07-26
PT1239832E (pt) 2004-10-29
RU2002119210A (ru) 2004-02-27
FR2802423B1 (fr) 2005-03-25
JP4588281B2 (ja) 2010-11-24
AU777619B2 (en) 2004-10-21
EP1437127A1 (de) 2004-07-14
HUP0203782A3 (en) 2005-01-28
CA2390029A1 (en) 2001-06-28
BE1014502A5 (fr) 2003-11-04
CO5261608A1 (es) 2003-03-31
HK1050474A1 (en) 2003-06-27
JP2003518036A (ja) 2003-06-03
RU2277912C2 (ru) 2006-06-20
DE60011809T2 (de) 2005-06-30
SK8652002A3 (en) 2002-12-03
CA2390029C (en) 2010-01-26
CN1411367A (zh) 2003-04-16
JP2006312651A (ja) 2006-11-16
ZA200204863B (en) 2003-03-17
SK287553B6 (sk) 2011-01-04
CN1216594C (zh) 2005-08-31
CZ20022138A3 (cs) 2002-09-11
AR030175A1 (es) 2003-08-13
US8119148B2 (en) 2012-02-21
KR20040098034A (ko) 2004-11-18
NZ518755A (en) 2004-04-30
EP1239832B1 (de) 2004-06-23
BR0016524A (pt) 2002-09-24

Similar Documents

Publication Publication Date Title
US8119148B2 (en) Suspension comprising oxcarbazepine
AU4308599A (en) A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer
RU2242231C2 (ru) Парентеральная композиция для лечения эпилепсии
EP4590277A1 (de) Pharmazeutische zusammensetzungen
AU2004203644B2 (en) Pharmaceutical compositions
WO2014149939A1 (en) Dye free liquid therapeutic solution
WO2019174755A1 (en) Oral solutions comprising tramadol and acetaminophen
HK1070267A (en) Suspension comprising oxcarbazepine
HK1050474B (en) Suspension comprising oxcarbazepine
WO2017038732A1 (ja) モンテルカストの含水医薬製剤
EP2968573A1 (de) Farbstofffreie flüssige therapeutische lösung

Legal Events

Date Code Title Description
MK1K Patent expired